Meng Zihui, Ye Zixuan, Zhu Pengrong, Zhu Jianguo, Fang Shuguang, Qiu Tianzhu, Li Yanan, Meng Lijuan
School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, China.
Wecare Probiotics Co., Ltd., Suzhou, China.
Front Microbiol. 2022 May 12;13:818793. doi: 10.3389/fmicb.2022.818793. eCollection 2022.
Despite the prevalence of breast cancer (BC), over half of BC cases are unrelated to known risk factors, which highlights the importance of uncovering more cancer-related factors. Currently, the microbiota has been proven to be a potent modulator of the tumor environment in BC, which regulates the immune balance in tumor-related networks. Through a large amount of data accumulation, the microbiota has shown many possibilities to reveal more insights into the development or control of BC. To expand the potential benefits of patients with BC, this study discusses the distribution profile and the effect mechanism of BC-related microbiota on tumors and further discusses its impact on different tumor therapies. Finally, we summarize the possibility of targeting microbiological therapies to improve BC treatment or in combination with other therapies.
尽管乳腺癌（BC）普遍存在，但超过一半的BC病例与已知风险因素无关，这凸显了发现更多癌症相关因素的重要性。目前，微生物群已被证明是BC肿瘤环境的有力调节因子，它调节肿瘤相关网络中的免疫平衡。通过大量数据积累，微生物群已显示出许多可能性，以揭示更多关于BC发生发展或控制的见解。为了扩大BC患者的潜在益处，本研究讨论了BC相关微生物群在肿瘤上的分布特征和作用机制，并进一步探讨其对不同肿瘤治疗的影响。最后，我们总结了靶向微生物治疗改善BC治疗或与其他治疗联合使用的可能性。
